Back to Research

Organization profile

Xemperia

Xemperia is a Swiss biotechnology company and a spinoff from the University of Fribourg, specializing in the development of a groundbreaking PCR-based blood test for the ultra-early detection of breast cancer. The company focuses on the systemic immune response to malignancy, providing a highly accurate, minimally invasive alternative to traditional imaging.10

Marly, SwitzerlandFounded 2023

Overview

1. Executive Summary (Confidence: High)

Xemperia represents the "cutting-edge" of the longevity biotech sector, focusing on the early detection of mortality drivers. Founded in December 2023 by Dr. Sarah Cattin and Prof. Curzio Rüegg, the company is the culmination of 25 years of research into the tumor microenvironment and immune response. Their proprietary technology uses PCR to analyze biomarkers in blood leukocytes that are "reprogrammed" by the presence of a tumor, even at the millimeter scale. With an accuracy rate of 99-100% in initial validation studies, Xemperia is preparing for large-scale clinical trials and aims for a market entry by 2028-2029. The company has already gained significant traction in the Swiss startup ecosystem, winning the IFF First Prize and the Ypsomed Innovation Award.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.